

Supplementary Materials

Uncovering the anti-lung cancer mechanisms of the herbal drug FDY2004 by network pharmacology

Ho-Sung Lee^{1,2}, In-Hee Lee¹, Kyungrae Kang², Sang-In Park³,
Tae-Wook Kwon², and Dae-Yeon Lee^{1,2},

¹The Fore, 87 Ogeum-ro, Songpa-gu, Seoul 05542, Republic of Korea.

²Forest Hospital, 129 Ogeum-ro, Songpa-gu, Seoul 05549, Republic of Korea.

³Forestheal Hospital, 173 Ogeum-ro, Songpa-gu, Seoul 05641, Republic of Korea.

Correspondence should be addressed to Dae-Yeon Lee; foresthrnd@gmail.com

Supplementary Figures

| | Category | Term name | Count | Percent [%] | p-value |
|---------------|--------------------|---|-------|-------------|----------|
| Gene ontology | Biological process | Cellular response to chemical stimulus | 101 | 2.95 | 1.93E-39 |
| | | Cellular response to chemical stress | 27 | 7.34 | 1.25E-15 |
| | | Cellular response to cytokine stimulus | 43 | 3.76 | 1.74E-15 |
| | | Cellular response to growth factor stimulus | 21 | 2.87 | 4.45E-04 |
| | | Cellular response to radiation | 14 | 7.25 | 6.53E-07 |
| | | Cellular response to stimulus | 117 | 1.50 | 9.93E-20 |
| | | Cytokine-mediated signaling pathway | 37 | 4.57 | 1.54E-15 |
| | | Integrated stress response signaling | 4 | 18.18 | 4.58E-02 |
| | | Lymphocyte activation | 19 | 2.45 | 1.82E-02 |
| | | Lymphocyte differentiation | 13 | 3.46 | 1.52E-02 |
| | | Regulation of angiogenesis | 16 | 3.88 | 2.69E-04 |
| | | Regulation of apoptotic process | 63 | 3.92 | 2.56E-26 |
| | | Regulation of apoptotic signaling pathway | 25 | 6.01 | 3.09E-12 |
| | | Regulation of catabolic process | 24 | 2.31 | 3.01E-03 |
| | | Regulation of catalytic activity | 59 | 2.46 | 6.18E-14 |
| | | Regulation of cell death | 67 | 3.80 | 1.04E-27 |
| | | Regulation of cell growth | 15 | 3.55 | 2.07E-03 |
| | | Regulation of cell migration | 37 | 3.73 | 1.09E-12 |
| | | Regulation of cell motility | 38 | 3.61 | 1.17E-12 |
| | | Regulation of cell population proliferation | 55 | 3.09 | 3.85E-17 |
| | | Regulation of cellular localization | 24 | 2.39 | 1.62E-03 |
| | | Regulation of cellular response to oxidative stress | 7 | 7.37 | 1.84E-02 |
| | | Regulation of cellular response to stress | 25 | 3.19 | 3.17E-06 |
| | | Regulation of cytokine production | 23 | 2.76 | 2.19E-04 |
| | | Regulation of immune response | 23 | 2.26 | 7.20E-03 |
| | | Regulation of immune system process | 44 | 2.67 | 1.86E-10 |
| | | Regulation of inflammatory response | 23 | 5.30 | 6.66E-10 |
| | | Regulation of kinase activity | 28 | 3.04 | 8.36E-07 |
| | | Regulation of leukocyte adhesion to vascular endothelial cell | 7 | 18.42 | 3.04E-05 |
| | | Regulation of leukocyte cell-cell adhesion | 19 | 5.65 | 2.96E-08 |
| | | Regulation of leukocyte differentiation | 14 | 4.76 | 1.44E-04 |
| | | Regulation of metabolic process | 95 | 1.31 | 6.28E-08 |
| | | Regulation of programmed cell death | 65 | 3.98 | 8.24E-28 |
| | | Regulation of response to oxidative stress | 7 | 6.73 | 3.34E-02 |
| | | Regulation of response to stimulus | 84 | 1.91 | 5.69E-16 |
| | | Regulation of response to stress | 46 | 2.98 | 7.02E-13 |
| | | Regulation of signal transduction | 71 | 2.19 | 2.10E-15 |
| | | Regulation of signaling | 76 | 2.05 | 2.22E-15 |
| | | Reponse to chemical | 113 | 2.35 | 1.82E-37 |
| | | Reponse to cytokine | 46 | 3.72 | 1.18E-16 |
| | | Reponse to drug | 27 | 6.44 | 3.42E-14 |
| | | Reponse to growth factor | 21 | 2.77 | 8.26E-04 |
| | | Reponse to radiation | 28 | 6.03 | 4.45E-14 |
| | | Reponse to stimulus | 124 | 1.31 | 7.20E-17 |
| | | Reponse to toxic substance | 13 | 5.20 | 1.56E-04 |

| | Category | Term name | Count | Percent [%] | p-value |
|---------------|---------------------|--|-------|-------------|----------|
| Gene ontology | Cellular components | Cell surface | 24 | 2.64 | 1.83E-05 |
| | | Chromatin | 22 | 1.75 | 4.57E-02 |
| | | Cytoplasm | 113 | 0.96 | 1.12E-03 |
| | | Cytosol | 61 | 1.17 | 1.28E-02 |
| | | Death-inducing signaling complex | 3 | 33.33 | 9.92E-03 |
| | | Endoplasmic reticulum | 37 | 2.01 | 3.84E-06 |
| | | Extracellular matrix | 14 | 2.53 | 2.01E-02 |
| | | Extracellular region | 56 | 1.22 | 9.27E-03 |
| | | Membrane region | 12 | 3.51 | 2.95E-03 |
| | | Nucleoplasm | 49 | 1.22 | 4.29E-02 |
| | | Organelle | 127 | 0.91 | 2.44E-04 |
| | | Plasma membrane | 65 | 1.15 | 9.60E-03 |
| | | Protein-containing complex | 63 | 1.14 | 1.77E-02 |
| | | Transcription regulator complex | 13 | 2.91 | 9.09E-03 |
| | | Vesicle | 54 | 1.34 | 8.84E-04 |
| | Molecular function | Catalytic activity | 96 | 1.63 | 3.39E-16 |
| | | Drug binding | 7 | 6.86 | 8.59E-03 |
| | | Enzyme binding | 55 | 2.41 | 3.71E-13 |
| | | Hormone binding | 6 | 6.98 | 3.34E-02 |
| | | Kinase activity | 23 | 2.85 | 2.86E-05 |
| | | Kinase binding | 22 | 2.91 | 3.88E-05 |
| | | Ligand-activated transcription factor activity | 9 | 20.45 | 2.47E-08 |
| | | Molecular transducer activity | 26 | 1.76 | 2.88E-02 |
| | | Nuclear receptor activity | 9 | 20.45 | 2.47E-08 |
| | | Phosphatase binding | 13 | 6.63 | 2.20E-06 |
| | | Signaling receptor activity | 26 | 1.76 | 2.88E-02 |
| | | Signaling receptor binding | 35 | 2.09 | 1.49E-05 |
| | | Small molecule binding | 49 | 1.90 | 1.98E-07 |
| | | Steroid hormone receptor activity | 9 | 16.36 | 2.07E-07 |
| | | Transcription factor binding | 28 | 3.97 | 3.14E-10 |
| Pathway | KEGG | Apoptosis | 13 | 9.56 | 2.00E-05 |
| | | Cellular senescence | 11 | 7.05 | 3.31E-03 |
| | | EGFR tyrosine kinase inhibitor resistance | 11 | 13.92 | 3.67E-06 |
| | | ErbB signaling pathway | 8 | 9.52 | 4.78E-03 |
| | | Estrogen signaling pathway | 11 | 8.03 | 9.77E-04 |
| | | Focal adhesion | 13 | 6.50 | 1.53E-03 |
| | | HIF-1 signaling pathway | 12 | 11.01 | 1.26E-05 |
| | | MAPK signaling pathway | 17 | 5.78 | 3.57E-04 |
| | | Non-small cell lung cancer | 9 | 13.24 | 1.02E-04 |
| | | p53 signaling pathway | 8 | 10.96 | 1.71E-03 |
| | | Pathways in cancer | 39 | 7.37 | 1.17E-14 |
| | | PD-L1 expression and PD-1 checkpoint pathway in cancer | 11 | 12.36 | 1.29E-05 |
| | | PI3K-Akt signaling pathway | 22 | 6.23 | 3.03E-06 |
| | | Platinum drug resistance | 9 | 12.50 | 1.67E-04 |
| | | Ras signaling pathway | 14 | 6.06 | 1.59E-03 |
| | | Small cell lung cancer | 10 | 10.87 | 1.63E-04 |
| | | TNF signaling pathway | 17 | 15.18 | 1.38E-10 |
| | | VEGF signaling pathway | 8 | 13.56 | 3.40E-04 |

Supplementary Figure S1. Functional enrichment analysis for the lung cancer-related targets of FDY2004.

Supplementary Tables

Supplementary Table S1. General information and reports on evidence of biological activities of FDY2004 and its herbal constituents

| Herbal medicines | | | | |
|------------------|---|--|---|--|
| | Moutan Radicis Cortex | Persicae Semen | Rhei Radix et Rhizoma | FDY2004 |
| Scientific name | <i>Paeonia suffruticosa</i> Andrews | <i>Prunus persica</i> Batsch | <i>Rheum palmatum</i> Linné | - |
| Vernacular name | <i>Mudanpi</i> | <i>Taoren</i> | <i>Dahuang</i> | - |
| Species | Paeoniaceae | Rosaceae | Rheum | - |
| Traditional uses | Treatment for allergic diseases, atherosclerosis, cutaneous diseases, diabetes, infection, and inflammation [1-4] | Treatment for dysmenorrhea, endometriosis, hypermenorrhea, and infertility [5-8] | Treatment for abdominal pain, constipation, fever, and intense and profuse sweating [9, 10] | - |
| Parts used | Root barks | Dried ripe seed | Dried root and rhizome | - |
| Collection site | China | Republic of South Africa | China | - |
| Yield | - | - | - | $19.07 \pm 2.14\% \text{ (w/w)}$ [11] |

| | | | | |
|-----------------------|---|---|---|--|
| Biological activities | Analgesic, anti-allergic, anticancer, antidiabetic, anti-inflammatory, anti-oxidative, antipyretic, hepatoprotective, immunomodulatory, and neuroprotective activities [4, 12-14] | Anti-allergic, anticancer, antidiabetic, anti-inflammatory, and anti-oxidative activities [15-20] | Anticancer, anti-fibrotic, anti-inflammatory, anti-oxidative, and gastrointestinal function regulatory activities [21-23] | Anticancer and antioxidant activities [11] |
|-----------------------|---|---|---|--|

Supplementary Table S2. Chemical components of FDY2004.

| Herbal medicines | Chemical compounds | OB | Caco-2 | DL |
|------------------|--|-------|--------|------|
| MRC | (+)-Catechin | 54.83 | -0.03 | 0.24 |
| MRC | 5-[[5-(4-methoxyphenyl)-2-furyl]methylene]barbituric acid {ZINC9320615} | 43.44 | 0.09 | 0.3 |
| MRC | Caffeic acid | 25.76 | 0.21 | 0.05 |
| MRC | Kaempferol | 41.88 | 0.26 | 0.24 |
| MRC | Mairin | 55.38 | 0.73 | 0.78 |
| MRC | Paeoniflorin | 10.22 | -1.69 | 0.79 |
| MRC | Paeoniflorin_qt | 68.18 | -0.34 | 0.4 |
| MRC | Paeonol | 28.79 | 0.93 | 0.04 |
| MRC | Pentagalloylglucose | 3.01 | -3.08 | 0.21 |
| MRC | Quercetin | 46.43 | 0.05 | 0.28 |
| MRC | (1R)-()-Nopinone | 57.86 | 1.23 | 0.05 |
| MRC | 1-(2,3-dihydroxy-4-methoxyphenyl)ethanone | 32.96 | 0.81 | 0.05 |

| | | | | |
|-----|---|--------|-------|------|
| MRC | 3-[(2S,3R,4S,5S,6R)-6-[[[(2R,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-4,5-dihydroxybenzoic acid | 5.6 | -2.54 | 0.63 |
| MRC | 3-acetyl-4-hydroxybenzoic acid | 37.58 | -0.04 | 0.05 |
| MRC | 3-Hydroxy-4-methoxyacetophenone | 22.32 | 0.85 | 0.04 |
| MRC | 4-O-Methylpaeoniflorin | 25.71 | -1.27 | 0.78 |
| MRC | 4-O-Methylpaeoniflorin_qt | 67.24 | 0.15 | 0.43 |
| MRC | 6-Hydroxycoumarin | 15.8 | 0.73 | 0.05 |
| MRC | 6-o-vanillyloxypaeoniflorin | 10.91 | -1.58 | 0.54 |
| MRC | 6-o-vanillyloxypaeoniflorin_qt 2 | 17.71 | -0.61 | 0.37 |
| MRC | apiopaeonoside | 16.73 | -1.79 | 0.64 |
| MRC | Apocynin | 31.71 | 0.74 | 0.04 |
| MRC | Benzoyl paeoniflorin | 31.14 | -1.35 | 0.54 |
| MRC | Beta-D-Apiose | 118.53 | -1.46 | 0.03 |
| MRC | Beta-sitosterol-beta-d-glucoside | 19.58 | -0.17 | 0.62 |
| MRC | Beta-sitosterol-beta-d-glucoside_qt | 25.32 | 1.28 | 0.75 |

| | | | | |
|-----|--|-------|-------|------|
| MRC | BOX | 31.55 | 0.54 | 0.02 |
| MRC | Sitosterol | 36.91 | 1.32 | 0.75 |
| MRC | Delta 7-stigmastenol | 25.32 | 1.31 | 0.75 |
| MRC | DEP | 52.19 | 0.72 | 0.07 |
| MRC | Eugenol | 56.24 | 1.35 | 0.04 |
| MRC | Galloyl-oxyphenoniflorin | 3.2 | -2.18 | 0.39 |
| MRC | Galloyl-oxyphenoniflorin_qt 2 | 26.21 | -0.54 | 0.44 |
| MRC | Hexanoic acid | 73.08 | 0.8 | 0.01 |
| MRC | Methyl salicylate | 42.55 | 1.05 | 0.03 |
| MRC | Mudanoside A | 13.39 | -1.42 | 0.29 |
| MRC | Mudanpinoic,acid,a | 13.86 | 0.6 | 0.65 |
| MRC | Mudanpioside H | 6.77 | -1.63 | 0.61 |
| MRC | Mudanpioside H_qt 2 | 42.36 | -0.39 | 0.37 |
| MRC | octadecyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate | 3.18 | 0.98 | 0.55 |
| MRC | Oleanic acid | 8.41 | 1.14 | 0.77 |

| | | | | |
|-----|--------------------|-------|-------|------|
| MRC | Oleanolic acid | 29.02 | 0.59 | 0.76 |
| MRC | Oleic acid | 33.13 | 1.17 | 0.14 |
| MRC | Oxypaeoniflorin | 12.98 | -1.91 | 0.78 |
| MRC | Oxypaeoniflorin_qt | 19.4 | -0.77 | 0.44 |
| MRC | Paeonidanin | 24.64 | -1.28 | 0.78 |
| MRC | Paeonidanin_qt | 65.31 | -0.09 | 0.35 |
| MRC | Paeonolide | 6.3 | -1.42 | 0.64 |
| MRC | Paeonoside | 18.52 | -0.86 | 0.24 |
| MRC | PHB | 30.15 | 0.39 | 0.03 |
| MRC | Trochol | 15.48 | 0.84 | 0.78 |
| MRC | Vanillic acid | 35.47 | 0.43 | 0.04 |
| MRC | WLN: QR CQ DV1 | 36.49 | 0.67 | 0.03 |
| PS | (+)-Epicatechin | 48.96 | 0.02 | 0.24 |
| PS | Amygdalin | 4.42 | -1.91 | 0.61 |
| PS | Campesterol | 37.58 | 1.31 | 0.71 |

| | | | | |
|----|--|--------|-------|------|
| PS | GA120 | 84.85 | 0.38 | 0.45 |
| PS | GA121-Isolactone | 72.7 | -0.26 | 0.54 |
| PS | GA122 | 64.79 | -0.17 | 0.5 |
| PS | GA122-Isolactone | 88.11 | -0.18 | 0.54 |
| PS | Gibberellin A119 | 76.36 | -0.12 | 0.49 |
| PS | Gibberellin A44 | 101.61 | -0.13 | 0.54 |
| PS | Gibberellin A7 | 73.8 | -0.18 | 0.5 |
| PS | Hederagenin | 36.91 | 1.32 | 0.75 |
| PS | α 1-Sitosterol | 43.28 | 1.41 | 0.78 |
| PS | (2S)-2-phenyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyacetic acid | 8.27 | -1.22 | 0.2 |
| PS | (2S,3R,4S,5S,6R)-2-(benzyloxy)-6-methylol-tetrahydropyran-3,4,5-triol | 17.14 | -0.71 | 0.14 |
| PS | [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (E)-3-(4-hydroxyphenyl)prop-2-enoate | 9.8 | -1.09 | 0.26 |
| PS | [2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate | 8.22 | -1.05 | 0.69 |

| | | | | |
|----|--|-------|-------|------|
| PS | 2,3-didehydro GA69 | 14.28 | -0.17 | 0.5 |
| PS | 2,3-didehydro GA77 | 88.08 | -0.67 | 0.53 |
| PS | 2,3-didehydro GA9 | 17.03 | 0.37 | 0.45 |
| PS | 24-Methylenecycloartanol | 10.4 | 1.42 | 0.79 |
| PS | 3-feruloylquinic acid | 19.31 | -1.01 | 0.36 |
| PS | 3-O-p-coumaroylquinic acid | 37.63 | -1.2 | 0.29 |
| PS | 4a-formyl-7alpha-hydroxy-1-methyl-8-methylidene-4aalpha,4bbeta-gibbane-1alpha,10beta-dicarboxylic acid | 88.6 | -0.75 | 0.46 |
| PS | 7-dehydroavenasterol | 10.03 | 1.36 | 0.76 |
| PS | alexandrin | 20.63 | -0.2 | 0.63 |
| PS | Amygdalinic acid | 4.15 | -2.32 | 0.63 |
| PS | Benzyl Beta -gentiobioside | 3.46 | -2.07 | 0.56 |
| PS | Benzyl glucopyranoside | 12.39 | -0.7 | 0.14 |
| PS | Beta-D-Glucopyranoside, 2-((benzoyloxy)methyl)-4-hydroxyphenyl | 13.51 | -1.03 | 0.53 |
| PS | Campesterol-3-O-β-D-(6-O-oleyl)glucopyranoside | 27.03 | 0.04 | 0.17 |

| | | | | |
|----|---|-------|-------|------|
| PS | Campesterol-3-O- β -D-(6-O-palmityl)glucopyranoside | 25.65 | 0.02 | 0.19 |
| PS | Campesterol-3-O- β -D-glucopyranoside | 20.49 | -0.22 | 0.67 |
| PS | Campesterol-3-O- β -D-glucopyranoside_qt | 7.86 | 1.29 | 0.72 |
| PS | cis-p-Coumarate | 45.98 | 0.46 | 0.04 |
| PS | D-mandelonitrile | 48.26 | 0.67 | 0.02 |
| PS | EIC | 41.9 | 1.16 | 0.14 |
| PS | GA118 | 10.41 | -0.6 | 0.53 |
| PS | GA121 | 14.13 | -0.26 | 0.5 |
| PS | GA126 | 11.8 | -0.64 | 0.53 |
| PS | GA16 | 14.26 | -0.63 | 0.53 |
| PS | GA30 | 61.72 | -0.83 | 0.54 |
| PS | GA54 | 64.21 | -0.5 | 0.53 |
| PS | GA60 | 93.17 | -0.79 | 0.53 |
| PS | GA61 | 14.82 | -0.22 | 0.49 |
| PS | GA63 | 65.54 | -0.57 | 0.54 |

| | | | | |
|----|---------------------------------|-------|-------|------|
| PS | GA69 | 17.67 | -0.21 | 0.49 |
| PS | GA70 | 14.04 | -0.23 | 0.49 |
| PS | GA77 | 87.89 | -0.64 | 0.53 |
| PS | GA87 | 68.85 | -1.14 | 0.57 |
| PS | GA95 | 20.01 | -0.24 | 0.49 |
| PS | GA97 | 10.12 | -0.89 | 0.47 |
| PS | Gibberellin 17 | 94.64 | -0.87 | 0.49 |
| PS | Grandidentatin | 10.56 | -0.9 | 0.54 |
| PS | Heriguard | 11.93 | -1.03 | 0.33 |
| PS | Methyl-alpha-D-fructofuranoside | 65.63 | -1.09 | 0.05 |
| PS | MGL | 24.46 | -1.13 | 0.05 |
| PS | MNN | 48.36 | 0.68 | 0.02 |
| PS | Triolein | 27.27 | 0.97 | 0.13 |
| PS | Prunasin | 12.61 | -0.79 | 0.18 |
| PS | RMN | 43.67 | 0.11 | 0.03 |

| | | | | |
|-----|--|-------|-------|------|
| PS | Salireposide_qt | 24.3 | 0.63 | 0.12 |
| PS | WLN: Q1R | 58.68 | 1.08 | 0.01 |
| PS | β -sitosterol 3-O- β -D-(6-O-oleyl)glucopyranoside | 26.94 | -0.02 | 0.16 |
| PS | β -sitosterol-3-(6-palmitoyl)glucopyranoside | 26.07 | 0.1 | 0.18 |
| RRR | (-)-Catechin | 49.68 | -0.03 | 0.24 |
| RRR | Aloe-emodin | 83.38 | -0.12 | 0.24 |
| RRR | Chrysophanol | 18.64 | 0.62 | 0.21 |
| RRR | Daucosterol {Sitogluside} | 20.18 | 0.09 | 0.69 |
| RRR | Daucosterol_qt | 35.89 | 1.35 | 0.7 |
| RRR | Emodin | 24.4 | 0.22 | 0.24 |
| RRR | Eupatin | 50.8 | 0.53 | 0.41 |
| RRR | Mutatochrome {Citroxanthin} | 48.64 | 1.97 | 0.61 |
| RRR | Palmidin A | 32.45 | -0.36 | 0.65 |
| RRR | Physcion | 22.29 | 0.52 | 0.27 |
| RRR | Rhein | 47.07 | -0.2 | 0.28 |

| | | | | |
|-----|--|-------|-------|------|
| RRR | Toralactone | 46.46 | 0.86 | 0.24 |
| RRR | Hispidulin | 29.95 | 0.47 | 0.27 |
| RRR | Procyanolidin B 3,3'-di-O-gallate | 42.63 | -1.86 | |
| RRR | Palmidin B | 1.21 | -0.11 | 0.69 |
| RRR | (-)Epicatechin-pentaacetate | 8 | -0.59 | 0.77 |
| RRR | (+)-Catechin-pentaacetate | 27.58 | -0.65 | 0.77 |
| RRR | (9S)-9-[(9R)-2-carboxy-4,5-dihydroxy-10-oxo-9H-anthracen-9-yl]-4,5-dihydroxy-10-oxo-9H-anthracene-2-carboxylic acid | 27.75 | -0.91 | 0.57 |
| RRR | [(2R,3R,4S,5R,6R)-3,5-dihydroxy-2-(3,4,5-trihydroxybenzoyl)oxy-6-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxan-4-yl] 3,4,5-trihydroxybenzoate | 3.01 | -2.22 | 0.54 |
| RRR | [(2R,3S,4S,5R,6S)-6-[4-[(Z)-2-(3,5-dihydroxyphenyl)ethenyl]phenoxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3,4,5-trihydroxybenzoate | 2.69 | -1.17 | 0.73 |
| RRR | [Epicatechin-(48)]5-epicatechin | 4.02 | -4.48 | 0 |
| RRR | 1,8-dihydroxy-3-methoxy-2,6-dimethyl-9,10-anthraquinone | 5.53 | 0.63 | 0.29 |
| RRR | 10beta-Hydroxy-6beta-isobutyrylfuranoeremophilane | 16.94 | 0.88 | 0.29 |
| RRR | 1-Cinnamoyl-3-hydroxy-11-methoxymeliacarpinin | 35.72 | -0.58 | 0.07 |

| | | | | |
|-----|--|-------|-------|------|
| RRR | 1-O-Galloyl-glycerol | 63.21 | -0.81 | 0.1 |
| RRR | 1-O-Galloylpedunculagin | 38.09 | -2.9 | 0.04 |
| RRR | 2,3-Digalloylglucose | 2.99 | -2.25 | 0.66 |
| RRR | 2-Cinnamoyl-glucose | 17.02 | -0.73 | 0.22 |
| RRR | 2-Methyl cardol | 3.56 | 1.46 | 0.28 |
| RRR | 2-Methyl-5-carboxymethyl-7-hydroxychromanone | 14.8 | 0.06 | 0.12 |
| RRR | 3,5-Di-O-galloyl-4-O-digalloylquinic acid | 3.01 | -2.61 | 0.31 |
| RRR | 3-Carboxy-4-hydroxy-phenoxy glucoside | 13.85 | -1.44 | 0.22 |
| RRR | 3-Hydroxy-25-norfriedel-3,1(10)-dien-2-one-30-oic acid | 18.4 | 0.41 | 0.78 |
| RRR | 5-[(Z)-2-(3-hydroxy-4-methoxy-phenyl)vinyl]resorcinol | 76.25 | 0.66 | 0.15 |
| RRR | 5-acetyl-7-hydroxy-2-methyl-chromone | 30.25 | 0.37 | 0.1 |
| RRR | 5-Carboxy-7-hydroxy-2-methyl-benzopyran-gamma-one | 34.4 | 0.14 | 0.11 |
| RRR | Aloeemodin-omega-O-beta-D-glucopyranoside | 9.04 | -1.34 | 0.81 |
| RRR | Anthraglycoside B | 27.06 | -1.29 | 0.8 |
| RRR | Barolub | 16.29 | 0.88 | 0.22 |

| | | | | |
|-----|--|-------|-------|------|
| RRR | Beta-Glucogallin | 17.89 | -1.58 | 0.25 |
| RRR | Chrysophanol glucoside | 20.06 | -1.17 | 0.76 |
| RRR | Chrysophanol-8-O-beta-D-(6'-O-galloyl)-glucopyranoside | 1.92 | -1.48 | 0.69 |
| RRR | Cinnamic acid | 19.68 | 0.91 | 0.03 |
| RRR | cis-Zimtsaeure | 38.19 | 0.91 | 0.03 |
| RRR | Citric acid | 56.22 | -1.11 | 0.05 |
| RRR | DLA | 44.51 | -0.21 | 0.01 |
| RRR | DMR | 68.62 | -1.09 | 0.02 |
| RRR | Docosanoate | 15.69 | 1.21 | 0.26 |
| RRR | Emodin-1-O-beta-D-glucopyranoside | 44.81 | -1.12 | 0.8 |
| RRR | Emodin-6-glucoside | 16.09 | -1.28 | 0.8 |
| RRR | Emodianthrone | 24.72 | 0.8 | 0.21 |
| RRR | Gallic acid-3-O-(6'-O-galloyl)-glucoside | 30.25 | -1.96 | 0.67 |
| RRR | Gallic acid-4-O-(6'-O-galloyl)-glucoside | 27.06 | -1.82 | 0.67 |
| RRR | Gallocatechin | 2.26 | -0.27 | 0.27 |

| | | | | |
|-----|--|-------|-------|------|
| RRR | Glycerite | 7.28 | -4.71 | 0.03 |
| RRR | Laccaic acid D | 2.06 | -0.56 | 0.31 |
| RRR | MAE | 65.06 | -0.46 | 0.01 |
| RRR | o-Acetyltoluene | 38.96 | 1.47 | 0.02 |
| RRR | OXL | 29.68 | -0.64 | 0.01 |
| RRR | Palmidin C | 2.35 | 0.18 | 0.69 |
| RRR | Physcion-8-O-beta-D-glucopyranoside | 8.2 | -1.19 | 0.85 |
| RRR | Physcion-9-O-beta-D-glucopyranoside_qt | 20.3 | 0.56 | 0.3 |
| RRR | Physciodiglucoside | 41.65 | -2.64 | 0.63 |
| RRR | Physcione | 19.38 | 0.02 | 0.27 |
| RRR | PIT | 72.29 | 0.64 | 0.13 |
| RRR | Procyanidin B-5,3'-O-gallate {Procyanidin} | 31.99 | -1.61 | 0.32 |
| RRR | RHAPONTIN | 9 | -0.86 | 0.55 |
| RRR | Rhapontisterone | 4.39 | -1.84 | 0.82 |
| RRR | Rheidin B | 1.21 | -0.19 | 0.65 |

| | | | | |
|-----|-------------------|-------|-------|------|
| RRR | Rheidin C | 1.24 | -0.18 | 0.58 |
| RRR | Rhein diglucoside | 2.93 | -2.79 | 0.63 |
| RRR | Rheinoside A | 0.82 | -3.17 | 0.68 |
| RRR | Rheinoside A_qt | 26.28 | -1.87 | 0.75 |
| RRR | Rheochrysin | 18.31 | -1.14 | 0.82 |
| RRR | Rheosmin | 26.79 | 0.97 | 0.04 |
| RRR | Rheumin | 9.16 | -0.23 | 0.17 |
| RRR | Sennidin C | 1.28 | -0.62 | 0.61 |
| RRR | Sennoside A | 3.34 | -3.7 | 0.08 |
| RRR | Sennoside B | 3.34 | -3.85 | 0.08 |
| RRR | Sennoside C | 3.99 | -3.54 | 0.09 |
| RRR | Sennoside D | 3.99 | -3.48 | 0.09 |
| RRR | Sennoside D_qt | 61.06 | -0.7 | 0.61 |
| RRR | Sennoside E | 3.02 | -3.67 | 0.06 |
| RRR | Sennoside E_qt | 50.69 | -0.74 | 0.61 |

| | | | | |
|---------|--|-------|-------|------|
| RRR | Serotonin | 42.99 | 0.59 | 0.06 |
| RRR | Strumaroside | 20.78 | -0.23 | 0.67 |
| RRR | Succinic acid | 29.62 | -0.44 | 0.01 |
| RRR | Torachrysone-8-O-beta-D-(6'-oxayl)-glucoside | 43.02 | -1.23 | 0.74 |
| RRR | TPBO | 24.23 | 1.42 | 0.03 |
| RRR | ZINC04081604 | 15.23 | 0.88 | 0.44 |
| MRC/RRR | 3,4,5-trihydroxybenzoic acid {Gallic acid} | 31.69 | -0.09 | 0.04 |
| PS/RRR | β -Sitosterol | 36.91 | 1.32 | 0.75 |

MRC, Moutan Radicis Cortex; PS, Persicae Semen; RRR, Rhei Radix et Rhizoma; OB, oral bioavailability; Caco-2, Caco-2 cell permeability; DL, drug-likeness score. Synonyms of certain chemical compounds are given in braces {}.

Supplementary Table S3. Active chemical components of FDY2004.

| Herbal medicines | Chemical compounds | OB | Caco-2 | DL |
|------------------|--|-------|--------|------|
| MRC | (+)-Catechin | 54.83 | -0.03 | 0.24 |
| MRC | 5-[[5-(4-methoxyphenyl)-2-furyl]methylene]barbituric acid {ZINC9320615} | 43.44 | 0.09 | 0.3 |
| MRC | Caffeic acid | 25.76 | 0.21 | 0.05 |
| MRC | Kaempferol | 41.88 | 0.26 | 0.24 |
| MRC | Mairin | 55.38 | 0.73 | 0.78 |
| MRC | Paeoniflorin | 10.22 | -1.69 | 0.79 |
| MRC | Paeonol | 28.79 | 0.93 | 0.04 |
| MRC | Pentagalloylglucose | 3.01 | -3.08 | 0.21 |
| MRC | Quercetin | 46.43 | 0.05 | 0.28 |
| MRC | Sitosterol | 36.91 | 1.32 | 0.75 |
| PS | (+)-Epicatechin | 48.96 | 0.02 | 0.24 |
| PS | Amygdalin | 4.42 | -1.91 | 0.61 |

| | | | | |
|-----|---------------------------|--------|-------|------|
| PS | Campesterol | 37.58 | 1.31 | 0.71 |
| PS | GA120 | 84.85 | 0.38 | 0.45 |
| PS | GA121-Isolactone | 72.7 | -0.26 | 0.54 |
| PS | GA122 | 64.79 | -0.17 | 0.5 |
| PS | GA122-Isolactone | 88.11 | -0.18 | 0.54 |
| PS | Gibberellin A119 | 76.36 | -0.12 | 0.49 |
| PS | Gibberellin A44 | 101.61 | -0.13 | 0.54 |
| PS | Gibberellin A7 | 73.8 | -0.18 | 0.5 |
| PS | Hederagenin | 36.91 | 1.32 | 0.75 |
| PS | α 1-Sitosterol | 43.28 | 1.41 | 0.78 |
| RRR | (-)-Catechin | 49.68 | -0.03 | 0.24 |
| RRR | Aloe-emodin | 83.38 | -0.12 | 0.24 |
| RRR | Chrysophanol | 18.64 | 0.62 | 0.21 |
| RRR | Daucosterol {Sitogluside} | 20.18 | 0.09 | 0.69 |
| RRR | Emodin | 24.4 | 0.22 | 0.24 |

| | | | | |
|---------|--|-------|-------|------|
| RRR | Eupatin | 50.8 | 0.53 | 0.41 |
| RRR | Mutatochrome {Citraxanthin} | 48.64 | 1.97 | 0.61 |
| RRR | Palmidin A | 32.45 | -0.36 | 0.65 |
| RRR | Physcion | 22.29 | 0.52 | 0.27 |
| RRR | Rhein | 47.07 | -0.2 | 0.28 |
| RRR | Toralactone | 46.46 | 0.86 | 0.24 |
| MRC/RRR | 3,4,5-trihydroxybenzoic acid {Gallic acid} | 31.69 | -0.09 | 0.04 |
| PS/RRR | β -Sitosterol | 36.91 | 1.32 | 0.75 |

MRC, Moutan Radicis Cortex; PS, Persicae Semen; RRR, Rhei Radix et Rhizoma; OB, oral bioavailability; Caco-2, Caco-2 cell permeability; DL, drug-likeness score. Synonyms of certain chemical compounds are given in braces { }.

Supplementary Table S4. Targets of active chemical components of FDY2004.

| Herbal medicines | Chemical compounds | Targets |
|------------------|-----------------------------|---|
| MRC | (+)-Catechin | ALPL*, APOB*, BACE1*, CA1, CA2, CA3, CA4*, CA5A, CA5B, CA6, CA7, CA9*, CA12*, CSF2*, DNMT1*, FUT4*, HMOX1*, KIAA1149, PGD*, PGF*, PON1*, PTGS2*, SLC22A11, SLC47A1 |
| MRC | Caffeic acid | ALOX5*, CA1, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9*, CA12*, CA14, MMP1*, MMP2*, MMP9*, NR0B2*, PTPN1*, SLC22A6 |
| MRC | Kaempferol | ABCB1*, ABCC1*, ABCG2*, AHR*, AKR1B1*, ALOX5*, AR*, CA2, CA7, CA12*, CDK1*, CISD1, CTDSP1, CYP1A2*, CYP1B1*, CYP2D6*, DAPK1, ESRRA*, FLT3*, HSD17B1*, HSD17B2*, MPO*, NOX4*, NR1I2*, P4HB, PTPRS, RPS6KA3*, SLC2A1*, TYR*, UGT1A3, UGT1A7*, UGT1A8, UGT1A9*, UGT3A1, XDH* |
| MRC | Mairin | A1CF, AKR1B10*, AMD1, ARHGEF7*, CDCA8*, CPSF4*, CYP2R1, DHPS, EIF2AK2*, EME1, FOLH1*, GPBAR1, HIGD1B, MDM2*, MEX3D, MMAB, MTOR*, POLB*, PTPRN, RAC1*, RNF31, RPS3, S100A8*, SAE1, UBA2*, USF1 |
| MRC | Mutatochrome {Citroxanthin} | DRAP1, NR1D2*, RANBP2, RUVBL1*, TJP1*, TPK1, YAP1* |
| MRC | Paeoniflorin | BLVRA, F13A1*, FRS3, HNRNPR, NUCB1, STRBP* |
| MRC | Paeonol | CASP8*, CASP10*, ICAM1*, MTNR1A*, MTNR1B, PTGS2*, TYR*, VCAM1* |

| | | |
|-----|---------------------|--|
| MRC | Pentagalloylglucose | ABCC11*, AMY1A, AMY1B, AMY1C, BACE1*, EGFR*, ESR1*, F10*, HMOX1*, MCL1, NFE2L2*, PTPN1*, PTPN2*, SERPINE1*, SQLE*, TMPRSS11D |
| MRC | Quercetin | ABCB1*, ABCC1*, ABCG2*, AKR1B1*, AKT1*, ALK*, ALOX12*, ALOX15*, ALOX5*, ATP5B, AURKB*, AVPR2*, AXL*, BACE1*, CA1, CA2, CA3, CA4*, CA5A, CA6, CA7, CA9*, CA12*, CA14, CAMK2B, CCR4*, CDK1*, CSNK2A1*, CXCR1*, CYP1A1*, CYP1A2*, CYP1B1*, CYP2C8*, CYP2C9*, DAPK1, DRD4*, EGFR*, ELAVL1*, F2*, FLT3*, GLO1, GPR35, GSK3B*, HCK, HIBCH, HSD17B2*, IGF1R*, KDR*, MAOA*, MCL1, MET*, MMP2*, MMP3*, MMP9*, MMP13*, MPO*, NEK2*, NEK6, NOX4*, NUAK1, P4HB*, PIK3R1, PIM1*, PKN1, PLA2G1B*, PTK2*, PTPRS, PYGL, SLC2A2, STK17B, XDH* |
| MRC | Sitosterol | CALML3, CYP17A1, DHPS, DRAP1, GPBAR1, HDLBP, LTF*, NPC1L1, NR1D2*, RAC1*, RUVBL1*, USF1 |
| PS | (+)-Epicatechin | ALPL, APOB, BACE1, CA1, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CA12, CSF2, DNMT1, FUT4, HMOX1, KIAA1149, PGD*, PGF*, PON1*, PTGS2*, SLC22A11, SLC47A1 |
| PS | Campesterol | AMD1, ARHGEF7, CALML3, CDCA8, CYP17A1, DHPS, DRAP1, EIF2AK2, GPBAR1, LTF*, MDM2*, MEX3D, MTOR*, NPC1L1, NR1D2*, PTPRN, RAC1*, RPS3, S100A8*, SHBG*, SLC10A1, SRD5A2*, TNNC1, USF1, USP8* |
| PS | GA120 | ACBD7, AMD1, CALML3, EIF2AK2, MDM2*, MEX3D, MTOR*, RAC1*, RPS3, S100A8* |

| | | |
|-----|---------------------------|--|
| PS | GA121-Isolactone | ARHGEF7, CPSF4, CYP2R1, DHRS1, EIF2AK2, FOLH1, MDM2*, MEX3D, MMAB, MTOR*, MTRR*, PHO85, PTPRN, RAC1*, RGS18, RPS3 |
| PS | GA122-Isolactone | DHRS1, MTRR*, RGS18 |
| PS | Gibberellin A44 | BRD7, DHRS1 |
| PS | Gibberellin A7 | ACBD7, EIF2AK2*, MDM2*, MEX3D, MTOR*, RAC1* |
| PS | Hederagenin | F3*, PNPN1, PTPN2* |
| PS | α 1-Sitosterol | ACBD7, AMD1, CALML3*, CDCA8*, DHPS, DRAP1, EIF2AK2*, HDLBP, LTF*, MDM2*, MEX3D, MTOR*, NR1D2*, RAC1*, RANBP2, RNF31, RUVBL1*, TNNC1, USF1, USP8* |
| RRR | (-)-Catechin | ALPL*, APOB*, BACE1*, CA1, CA2, CA3, CA4*, CA5A, CA5B, CA6, CA7, CA9*, CA12*, CSF2*, DNMT1*, FUT4*, HMOX1*, KIAA1149, PGD*, PGF*, PON1*, PTGS2*, SLC22A11, SLC47A1 |
| RRR | Aloe-emodin | CASP3*, CASP8*, CASP9*, EIF2S1, HSP90AA1*, TP53*, UGT1A9*, XBP1* |
| RRR | Chrysophanol | NLRP3*, UGT1A9* |
| RRR | Daucosterol {Sitogluside} | CYP17A1*, NPC1L1, NR1D2*, RUVBL1* |
| RRR | Emodin | AKR1B1*, CASP3*, CSNK2A1*, CSNK2B, CXCR4*, CYP1B1*, ERBB2*, ESR1*, ESR2*, LCK*, MCL1, PIM1*, PTP4A3*, TNF*, TP53*, VEGFA* |

| | | |
|---------|---|--|
| RRR | Eupatin | CREB1*, CYP1B1* |
| RRR | Physcion | ELANE*, UGT1A9* |
| RRR | Rhein | DNM1L*, FTO*, NFKB1*, PPARA*, PPARG*, RELA*, RXRA*, SLC37A4, TPMT*, UCP1, VEGFA* |
| MRC/RRR | 3,4,5-trihydroxybenzoic acid {Gallic acid} | ABCB1*, ATM*, CA1, CA2, CA3, CA4*, CA5A, CA5B, CA6, CA7, CA9*, CA12*, CA14, CASP3*, EIF2AK3*, FUT7*, GATA3*, JUN*, MMP2*, SERPINE1*, TPMT*, TYR*, UGT2B17* |
| PS/RRR | β -Sitosterol | ACBD7, CYP17A1*, DHPS, DRAP1, GPBAR1, LTF*, MDM2*, MEX3D, MTOR*, NPC1L1, NR1D2, RAC1*, RANBP2, RUVBL1*, TNNC1, USF1 |

MRC, Moutan Radicis Cortex; PS, Persicae Semen; RRR, Rhei Radix et Rhizoma; *, lung cancer-associated targets. Synonyms of certain chemical compounds are given in braces {}.

Supplementary Table S5. Docking scores between active chemical components of FDY2004 and the lung cancer-associated targets.

| Chemical compounds | Targets | | | | | | | | | | | |
|--------------------|---------|------|------|----------|------|-------|--------|------|-------|------|------|-------|
| | AKT1 | EGFR | ESR1 | HSP90AA1 | JUN | NFKB1 | PIK3R1 | PTK2 | RAC1 | TNF | TP53 | VEGFA |
| (-)-Catechin | -5.7 | -7.7 | -7.0 | -6.7 | -5.3 | -6.3 | -6.1 | -6.0 | -8.5 | -6.2 | -7.3 | -6.9 |
| (+)-Catechin | -6.0 | -7.7 | -7.0 | -6.7 | -5.3 | -6.3 | -6.1 | -6.0 | -9.0 | -6.2 | -7.3 | -6.9 |
| (+)-Epicatechin | -5.6 | -7.7 | -7.0 | -6.7 | -5.3 | -6.4 | -6.1 | -6.0 | -9.0 | -6.3 | -7.3 | -6.9 |
| Aloe-emodin | -6.1 | -8.3 | -7.4 | -7.2 | -5.4 | -6.4 | -6.0 | -6.1 | -9.6 | -6.4 | -7.1 | -6.8 |
| Caffeic acid | -5.2 | -6.5 | -5.1 | -5.8 | -4.6 | -5.3 | -5.0 | -4.8 | -6.8 | -4.9 | -5.8 | -5.5 |
| Campesterol | -6.0 | -9.4 | -6.4 | -5.7 | -5.8 | -5.8 | -6.0 | -5.9 | -8.3 | -5.6 | -6.2 | -7.9 |
| Chrysophanol | -5.7 | -8.5 | -7.6 | -7.3 | -5.4 | -6.5 | -5.8 | -6.0 | -9.8 | -6.7 | -7.3 | -7.0 |
| Daucosterol | -5.3 | -7.2 | -8.1 | -5.1 | -5.8 | -6.9 | -6.0 | -6.7 | -8.8 | -5.9 | -6.6 | -7.9 |
| Emodin | -6.0 | -8.3 | -7.8 | -7.2 | -5.6 | -6.5 | -5.8 | -6.2 | -10.1 | -6.8 | -7.3 | -7.0 |
| Eupatin | -5.5 | -8.7 | -6.8 | -6.0 | -5.4 | -6.8 | -5.7 | -6.0 | -9.3 | -6.7 | -6.6 | -7.1 |
| GA120 | -6.9 | -8.2 | -7.3 | -7.4 | -6.7 | -6.5 | -6.7 | -6.2 | -8.4 | -6.1 | -7.1 | -7.5 |
| Gallic acid | -5.4 | -6.4 | -5.4 | -5.2 | -5.1 | -5.2 | -4.9 | -4.6 | -6.3 | -4.8 | -5.4 | -5.6 |

| | | | | | | | | | | | | |
|-----------------------|------|-------|------|------|------|------|------|------|-------|------|------|-------|
| Gibberellin A7 | -6.0 | -7.9 | -7.0 | -7.2 | -6.5 | -6.4 | -6.5 | -6.2 | -8.1 | -6.4 | -6.9 | -7.4 |
| Hederagenin | -6.5 | -10.0 | -7.9 | -5.0 | -6.6 | -6.5 | -7.5 | -6.9 | -7.7 | -6.5 | -7.4 | -7.8 |
| Kaempferol | -6.3 | -7.9 | -6.6 | -6.3 | -5.4 | -6.4 | -6.1 | -5.7 | -8.8 | -6.3 | -6.7 | -6.9 |
| Mairin | -5.0 | -9.8 | -7.9 | -6.5 | -6.8 | -6.5 | -6.8 | -6.7 | -6.8 | -6.6 | -7.8 | -8.3 |
| Mutatochrome | -6.9 | -5.4 | -7.3 | -6.5 | -7.3 | -7.7 | -7.8 | -7.2 | -10.3 | -6.2 | -7.6 | -9.6 |
| Paeoniflorin | -6.0 | -8.6 | -7.0 | -6.1 | -6.1 | -6.8 | -6.7 | -7.2 | -8.4 | -5.7 | -6.6 | -7.6 |
| Paeonol | -5.3 | -5.7 | -5.0 | -5.4 | -3.9 | -4.9 | -4.5 | -4.1 | -6.3 | -4.9 | -5.2 | -5.1 |
| Pentagalloylglucose | -6.0 | -8.9 | -7.0 | -3.0 | -6.0 | -8.7 | -6.3 | -7.0 | -8.9 | -7.0 | -8.3 | -8.4 |
| Physcion | -8.1 | -11.2 | -9.9 | -6.3 | -7.8 | -8.8 | -8.0 | -9.1 | -12.7 | -8.3 | -8.8 | -10.4 |
| Quercetin | -6.4 | -7.9 | -6.5 | -6.1 | -5.4 | -6.6 | -6.3 | -6.1 | -9.3 | -6.5 | -7.0 | -7.2 |
| Rhein | -5.4 | -8.7 | -7.6 | -6.7 | -5.6 | -6.8 | -6.1 | -6.2 | -10.2 | -6.4 | -7.3 | -7.1 |
| Sitosterol | -4.5 | -8.8 | -6.2 | -5.5 | -5.8 | -5.3 | -5.9 | -5.9 | -8.1 | -5.6 | -6.4 | -7.8 |
| α 1-Sitosterol | -4.8 | -9.7 | -6.3 | -6.8 | -6.3 | -5.5 | -5.9 | -5.9 | -7.8 | -5.5 | -7.0 | -8.5 |
| -Sitosterol | -4.5 | -8.8 | -6.2 | -5.2 | -5.9 | -5.3 | -5.8 | -5.8 | -7.0 | -5.6 | -6.8 | -7.9 |

References

1. M. Zhang, L. Feng, J. Gu, et al. "The attenuation of Moutan Cortex on oxidative stress for renal injury in AGEs-induced mesangial cell dysfunction and streptozotocin-induced diabetic nephropathy rats," *Oxid Med Cell Longev*, vol. 2014, p. 463815.
2. H.S. Choi, H.S. Seo, J.H. Kim, J.Y. Um, Y.C. Shin, and S.G. Ko. "Ethanol extract of paeonia suffruticosa Andrews (PSE) induced AGS human gastric cancer cell apoptosis via fas-dependent apoptosis and MDM2-p53 pathways," *J Biomed Sci*, vol. 19, p. 82.
3. H.S. Kim, A.R. Kim, J.M. Lee, et al. "A mixture of Trachelospermi caulis and Moutan cortex radicis extracts suppresses collagen-induced arthritis in mice by inhibiting NF-kappaB and AP-1," *J Pharm Pharmacol*, vol. 64, no. 3, pp. 420-429.
4. S.Y. Zong, Y.Q. Pu, B.L. Xu, T. Zhang, and B. Wang. "Study on the physicochemical properties and anti-inflammatory effects of paeonol in rats with TNBS-induced ulcerative colitis," *Int Immunopharmacol*, vol. 42, pp. 32-38.
5. W. Jia, X. Wang, D. Xu, A. Zhao, and Y. Zhang. "Common traditional Chinese medicinal herbs for dysmenorrhea," *Phytother Res*, vol. 20, no. 10, pp. 819-824.
6. H.Y. Chen, Y.H. Lin, I.H. Su, Y.C. Chen, S.H. Yang, and J.L. Chen. "Investigation on Chinese herbal medicine for primary dysmenorrhea: implication from a nationwide prescription database in Taiwan," *Complement Ther Med*, vol. 22, no. 1, pp. 116-125.
7. H.J. Kim, K.K. Park, W.Y. Chung, S.K. Lee, and K.R. Kim. "Protective Effect of White-fleshed Peach (*Prunus persica* (L.) Batsch) on Chronic Nicotine-induced Toxicity," *J Cancer Prev*, vol. 22, no. 1, pp. 22-32.
8. C. Burks-Wicks, M. Cohen, J. Fallbacher, N.T. R, and F. Wieser. "A Western primer of Chinese herbal therapy in endometriosis and infertility," *Womens Health (Lond)*, vol. 1, no. 3, pp. 447-463.
9. Y.C. Wu, P. Wu, Y.B. Li, T.C. Liu, L. Zhang, and Y.H.J.R.a. Zhou. "Natural deep eutectic solvents as new green solvents to extract anthraquinones from *Rheum palmatum* L," *RSC Adv*, vol. 8, no. 27, pp. 15069-15077.

10. Y. Fan, Z. Niu, C. Xu, L. Yang, and T. Yang. "Protic Ionic Liquids as Efficient Solvents in Microwave-Assisted Extraction of Rhein and Emodin from *Rheum palmatum* L," *Molecules*, vol. 24, no. 15.
11. I.-H. Lee, H.-S. Lee, K. Kang, et al. "Influence of Decoction Duration of FDY2004 on Its Physicochemical Components and Antioxidant and Antiproliferative Activities," *Nat Prod Commun*, vol. 15, no. 10, p. 1934578X20968437.
12. M.H. Zhang, L. Feng, M.M. Zhu, et al. "The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and High-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats," *J Ethnopharmacol*, vol. 151, no. 1, pp. 591-600.
13. P.K. Fu, C.Y. Yang, T.H. Tsai, and C.L. Hsieh. "Moutan cortex radicis improves lipopolysaccharide-induced acute lung injury in rats through anti-inflammation," *Phytomedicine*, vol. 19, no. 13, pp. 1206-1215.
14. Z. Wang, C. He, Y. Peng, F. Chen, and P. Xiao. "Origins, Phytochemistry, Pharmacology, Analytical Methods and Safety of Cortex Moutan (*Paeonia suffruticosa* Andrew): A Systematic Review," *Molecules*, vol. 22, no. 6.
15. G.J. Kim, H.G. Choi, J.H. Kim, S.H. Kim, J.A. Kim, and S.H. Lee. "Anti-allergic inflammatory effects of cyanogenic and phenolic glycosides from the seed of *Prunus persica*," *Nat Prod Commun*, vol. 8, no. 12, pp. 1739-1740.
16. K.H. Seo, S.Y. Choi, Y. Jin, et al. "Antiinflammatory role of *Prunus persica* L. Batsch methanol extract on lipopolysaccharidestimulated glial cells," *Mol Med Rep*, vol. 21, no. 5, pp. 2030-2040.
17. W. Cassiem and M. de Kock. "The anti-proliferative effect of apricot and peach kernel extracts on human colon cancer cells in vitro," *BMC Complement Altern Med*, vol. 19, no. 1, p. 32.
18. T. Fukuda, H. Ito, T. Mukainaka, H. Tokuda, H. Nishino, and T. Yoshida. "Anti-tumor promoting effect of glycosides from *Prunus persica* seeds," *Biol Pharm Bull*, vol. 26, no. 2, pp. 271-273.
19. R. Kant, R.K. Shukla, A.J.I.J.F.R.I.A.S. Shukla, and E. Technology. "A review on Peach (*Prunus persica*): an asset of medicinal phytochemicals," *Int J Res Appl Sci Eng Technol*, vol. 6, no. I.

20. S. Kim, S.Y. Hong, B. Kwon, et al. "Effect of Persicae Semen for Atopic Dermatitis Skin Tissue and Regulate to Inflammation Mediator in Serum," *Korea J Herbol*, vol. 35, no. 4, pp. 51-60.
21. C.S. Shia, S.H. Juang, S.Y. Tsai, et al. "Metabolism and pharmacokinetics of anthraquinones in Rheum palmatum in rats and ex vivo antioxidant activity," *Planta Med*, vol. 75, no. 13, pp. 1386-1392.
22. Z.B. Tan, H.J. Fan, Y.T. Wu, et al. "Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling," *J Ethnopharmacol*, vol. 232, pp. 62-72.
23. H. Xiang, J. Zuo, F. Guo, and D. Dong. "What we already know about rhubarb: a comprehensive review," *Chin Med*, vol. 15, p. 88.